An observational study in Congenital Heart Disease, ICU Acquired Weakness and Catabolic State, sponsored by Boston Children's Hospital. Recruiting at 1 site in United States. Open to participants aged 3 Months to 18 Years. Per ClinicalTrials.gov, last updated 2023-07-19.
Sponsored by Boston Children's Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 37 studies in Heart Defects, Congenital by Boston Children's Hospital — 9 open to participants now, 10 under way, none of them phase 3. Heart Defects, Congenital · Boston Children's Hospital.
Among the 37 studies in Heart Defects, Congenital by Boston Children's Hospital, this one is the 10th largest by planned enrollment of the 19 observational ones that give a count, is one of 5 that started in 2022, is one of 19 observational ones, and was the 28th registered.
992 studies on the registry are indexed under Heart Defects, Congenital; 252 are open to participants now.
Browse Heart Defects, Congenital studies →9 of the 37 studies in Heart Defects, Congenital by Boston Children's Hospital are open now, in 1 country. Recruiting first, the newest first:
Boston Children's Hospital · Sites in United States
Ages 1 days–12 yrs
Boston Children's Hospital · Sites in United States
Ages 1 days–7 days
Boston Children's Hospital · Sites in United States
Ages 24–35 · Healthy volunteers
Boston Children's Hospital · Sites in United States
Boston Children's Hospital · Sites in United States
Ages 2 days–5 yrs
By country, each count listing its studies:
Of the 156 Heart Defects, Congenital studies recruiting now, 69 (44%) set no upper age limit and 79 (51%) stop at 75 or younger; 112 take children under 18; 25 take healthy volunteers.
This study: 3 Months to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
37 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 2 · Phase 4 1
First in 1988; this study’s year is marked. 5 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 64 is below the median of 119 across 440 observational studies indexed under Heart Defects, Congenital.
Median enrollment 37 across the 18 interventional studies, 64 across the 19 observational. Of the 24 that completed or were terminated, 4 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
Boston Children's Hospital is the lead sponsor of 609 studies on the registry; 148 are open to participants now.
Of its 32 completed or terminated interventional studies of FDA-regulated products, 19 (59%) have results posted.
6 of the studies in Heart Defects, Congenital by Boston Children's Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04299828Boston Children's HospitalEvaluation of Pro-Inflammatory Leukocyte Activity in Patients Undergoing Cardiac Surgery | 2026-12 |
| NCT06642662Boston Children's HospitalPrecision Medicine in the CICU: Identifying Proteomic Biomarkers | 2026-12-01 |
| NCT06434207Boston Children's HospitalExtracellular Vesicle Micro RNA Profiling in Congenital Heart Disease: Fetal-Maternal Regulation in Neonatal Thrombosis | 2026-12-01 |
| NCT06899971Boston Children's HospitalThe Association Between Tau & GFAP and Postoperative Neurological Impairment in Patients Undergoing Cardiac Surgery | 2026-12-31 |
| NCT07361523Boston Children's HospitalUsing Near-Infrared Spectroscopy Devices to Assess Myocardial and Visceral Perfusion During Complex Congenital Cardiac Surgery | 2026-12-31 |
Add all 6 to your calendar (.ics) → With an account.
Among the 37 studies in Heart Defects, Congenital by Boston Children's Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Background \& Significance. Children with congenital heart disease (CHD) have experienced improved postoperative survival shifting the focus away from minimizing mortality to curtailing morbidities. Critical illness following cardiac surgery induces catabolism which may impact functional status. Catabolism, a state in which protein breakdown exceeds protein synthesis, can lead to lean body mass (LBM) breakdown. LBM loss has been associated with poor clinical outcomes. Muscle ultrasound (mUS) has been utilized to measure LBM changes and the functional status score (FSS) was developed to assess functional status changes in children following hospitalization. The ability to identify LBM loss acutely and its association with FSS changes may lead to earlier interventions to preserve LBM and aid in outcome prediction.
Specific Aims \& Hypotheses. Specific Aim 1 is to identify the percent change in LBM by mUS during the first postoperative week in children following complex cardiac surgery. Specific Aim 2 is to evaluate the relationship between percent change in LBM during the first postoperative week and the FSS at discharge and 6 and 12-month follow-up in children with CHD following complex cardiac surgery. The investigators hypothesize children with CHD following complex cardiac surgery will experience a decline in LBM and that there is a direct relationship between the change in LBM and postoperative FSS follow-up.
Study Design \& Methods. The investigators are conducting a single-center, prospective, observational cohort study. Consecutive children (> 3 months and \< 18 years of age) with CHD undergoing biventricular conversion will be enrolled. Patients will undergo a baseline mUS and FSS at the time of the index operation. Interval mUS will be obtained on the third and seventh postoperative day. Discharge mUS and FSS will be obtained and a remote FSS will be requested by the family at 6 and 12-months postoperatively. Demographics, pertinent laboratory, concomitant medications, nutrition and ultrasound variables will be collected.
Outcomes. The primary outcomes will be change in LBM during the first postoperative week and change in FSS at 6 and 12-month follow-up in children following complex cardiac surgery. Change in LBM will be defined as a percent change in cross-sectional area of the quadriceps muscle layer thickness (QMLT). Change in FSS will be significant if the score drops 3 points or more from baseline at postoperative follow-up.
The central objective of our single center, pilot study in children with CHD following cardiac surgery is to identify serial changes in QMLT, as an estimate of LBM, during the first postoperative week, and to examine its relationship to functional status, assessed by FSS, after hospital discharge.
Primary Aim 1. To measure the percent change in QMLT by mUS during the first postoperative week in children undergoing complex cardiac surgery. The investigators hypothesize children undergoing complex cardiac surgery will have a mean decline of at least 10% in QMLT during the first postoperative week.
Primary Aim 2. To examine the relationship between percent change in QMLT during the first postoperative week and FSS at 3 and 6-months. The investigators hypothesize there is a direct relationship between percent change in QMLT during the first postoperative week and FSS at 3 and 6-months following surgery.
Secondary Aim 1. To explore the relationship between nitrogen balance, defined as the difference between total nitrogen intake and total urinary nitrogen loss, and mean change in QMLT during the first postoperative week. The investigators hypothesize there is a direct correlation between nitrogen balance and mean change in QMLT during the first postoperative week in children following complex cardiac surgery.
The proposed utilization of mUS to measure alterations in body composition during the acute phase of critical illness may provide early prediction of subsequent functional status decline.
Children with congenital heart disease admitted to the cardiac intensive care unit following complex cardiac surgery.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The investigators will perform serial muscle ultrasounds in the postoperative period to estimate lean body mass.
Change in lean body mass
The investigators are measuring the change in lean body mass estimated by quadriceps muscle layer thickness (QMLT)
Time frame: 7 days postoperatively
Change in functional status
The investigators will measure functional status at 6 and 12-month follow-up to investigate the association between change in QMLT and functional status
Time frame: 6 and 12 months
Relationship of nitrogen balance to lean body mass changes
The investigators will measure urinary nitrogen balance to investigate its relationship to mean change in QMLT during the first postoperative week
Time frame: 12-24 hours postoperatively
Plan to share: No — Participant data will not be shared with other researchers.
No publications or documents are linked to this record.
Started Jul 2022 (actual). Primary completion is estimated for Dec 2023, 17 months after the start.
Of 178 non-industry observational studies under Heart Defects, Congenital, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 83. This study's planned 17 months is below that.
Counting every sponsor, half of 185 studies reached it within 44 months; a quarter within 17 and three quarters within 83.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.